FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.

• 

  FDA approves weight loss drug Zepbound for sleep apnea

  Zepbound, Eli Lilly’s weight loss drug, can now be used to treat obstructive sleep apnea in adults with obesity, the FDA said.
  
  NBC News - 3h

• Eli Lilly given US approval to treat sleep disorder with weight-loss drug

  Regulatory go-ahead marks latest boost for drugmaker’s blockbuster anti-obesity franchise
  
  Financial Times - 3h
• 

  F.D.A. Approves Weight-Loss Drug to Treat Sleep Apnea

  Zepbound is the first prescription drug approved specifically to treat the common condition.
  
  The New York Times - 4h

• FDA says Eli Lilly's weight loss drug Zepbound is no longer in shortage

  The decision that will eventually bar compounding pharmacies from making unbranded versions of the injection.
  
  CNBC - 1d
• 

  FDA warns companies over unapproved weight loss drug sales

  The Food and Drug Administration (FDA) said Tuesday in a statement it has sent warning letters to companies selling unapproved weight loss drugs. The letter went to Xcel Peptides, Swisschems, ...
  
  The Hill - 2d

• Ro to offer lower-price vials of weight loss drug Zepbound by teaming up with Eli Lilly

  It is made possible through a first-of-a-kind integration with Eli Lilly's direct-to-consumer website, and aims to streamline access to the popular treatment.
  
  CNBC - Dec. 11
• 

  Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, Zepbound

  Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products
  
  ABC News - Dec. 5

• Eli Lilly says Zepbound’s weight-loss results beat those of rival Wegovy

  Zepbound helped patients lose more weight than a major rival in a head-to-head trial.
  
  MarketWatch - Dec. 4

• Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial

  Zepbound's greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of the weight loss drug market.
  
  CNBC - Dec. 4

More from CNBC

• Government shutdown: House passes stopgap funding bill, sends it to Senate for vote

  CNBC - 1h

• CFPB sues JPMorgan Chase, Bank of America and Wells Fargo over Zelle payment fraud

  CNBC - 6h

• Key Fed inflation measure shows 2.4% rate in November, lower than expected

  CNBC - 11h

• Jim Cramer explains how to spot 'exquisite moments' like Friday's session

  CNBC - 2h

• OpenAI is done with Shipmas and staring down daunting challenges for 2025

  CNBC - 7h